# Sample sentences for speech fine-tuning data generation
# Medical terminology - Head and Neck Oncology

# Dysgeusia
The patient reports dysgeusia that began two weeks after starting radiation therapy.
Dysgeusia is a common side effect of head and neck radiation treatment.
Management of dysgeusia includes zinc supplementation and proper oral hygiene.
Severe dysgeusia can lead to decreased appetite and weight loss.

# Radiation
Radiation therapy will target the primary tumor and regional lymph nodes.
The total radiation dose will be sixty-six gray in thirty-three fractions.
Intensity modulated radiation therapy helps spare normal tissue.
Radiation-induced mucositis typically peaks during the fourth week of treatment.
Daily radiation treatments are scheduled Monday through Friday.

# Adenoid cystic carcinoma
Adenoid cystic carcinoma has a tendency for perineural invasion.
The pathology confirmed adenoid cystic carcinoma of the salivary gland.
Adenoid cystic carcinoma often requires postoperative radiation therapy.
This tumor is consistent with adenoid cystic carcinoma on frozen section.

# Tonsil
The primary tumor is located in the right palatine tonsil.
Tonsil cancer is commonly associated with HPV infection.
The tonsil mass measures three centimeters in greatest dimension.
Bilateral tonsil asymmetry was noted on physical examination.

# Lacrimal gland
The tumor involves the lacrimal gland with orbital extension.
Adenoid cystic carcinoma of the lacrimal gland requires aggressive treatment.
The lacrimal gland will be included in the radiation field.
MRI demonstrates enhancement of the left lacrimal gland.

# Base of tongue
The tumor originates at the base of tongue on the right side.
Base of tongue cancers often present at advanced stages.
The base of tongue receives sixty-six gray in the treatment plan.
Dysphagia is common with base of tongue tumors.

# Floor of mouth
The lesion is located in the anterior floor of mouth.
Floor of mouth cancer may invade the mandible.
The floor of mouth appears normal on clinical examination.
Surgical resection included the floor of mouth and sublingual gland.

# HPV
HPV-positive oropharyngeal cancer has a better prognosis.
HPV testing was performed on the tumor specimen.
The patient has HPV-associated squamous cell carcinoma.
HPV status is an important prognostic factor.

# MSKCC
The patient is being treated at MSKCC in New York.
MSKCC guidelines recommend concurrent chemoradiation for this stage.
The case was discussed at the MSKCC tumor board.
MSKCC has extensive experience with this rare malignancy.

# Combined phrases
The HPV-positive tonsil cancer will be treated with radiation therapy.
Dysgeusia improved six months after completing radiation to the base of tongue.
MSKCC protocols for adenoid cystic carcinoma include postoperative radiation.
The floor of mouth and base of tongue were included in the high-dose volume.
Lacrimal gland tumors often require radiation doses similar to those for tonsil cancer.
HPV testing is routinely performed for all tonsil and base of tongue cancers.
The patient developed dysgeusia during radiation for floor of mouth cancer.
Adenoid cystic carcinoma of the lacrimal gland has a high rate of local recurrence.
MSKCC recommends close surveillance for HPV-negative base of tongue tumors.
Radiation-induced dysgeusia typically resolves within one year after treatment.

# EGFR inhibitors
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor.
The patient will start osimertinib at eighty milligrams daily.
Tagrisso is the brand name for osimertinib.
Osimertinib has activity against the T790M resistance mutation.
The patient tolerates osimertinib with minimal side effects.

# Antibody-drug conjugates
Dato-DXD is an investigational antibody-drug conjugate.
The ADC was administered at the recommended phase two dose.
Antibody-drug conjugate therapy combines targeted delivery with cytotoxic payload.
ADC development has revolutionized targeted cancer therapy.
The patient is enrolled in a dato-DXD clinical trial.

# Immunotherapy
Pembrolizumab is a PD-1 checkpoint inhibitor.
The patient receives pembrolizumab every three weeks.
Keytruda is the brand name for pembrolizumab.
Nivolumab was approved for use in combination with chemotherapy.
IO therapy has improved outcomes in many cancer types.
Immunotherapy is considered for patients with high PD-L1 expression.
The patient had an excellent response to pembrolizumab.
Nivolumab and pembrolizumab are both anti-PD-1 antibodies.

# Chemotherapy agents
Cisplatin is the most common chemotherapy used with radiation.
The patient will receive weekly cisplatin during radiation therapy.
Paclitaxel is administered every three weeks.
Carboplatin is often substituted when cisplatin is contraindicated.
The regimen consists of carbo and paclitaxel.
Carbo-taxol is well-tolerated in elderly patients.
Weekly carboplatin may be used instead of cisplatin for concurrent therapy.

# Combined treatment regimens
The patient received pembrolizumab after completing cisplatin and radiation.
Osimertinib is continued as maintenance therapy after chemoradiation.
Immunotherapy with nivolumab was started six weeks after radiation.
The treatment plan includes carbo-taxol followed by pembrolizumab.
Keytruda is being evaluated in combination with radiation therapy.
Dato-DXD shows promise in ADC-resistant disease.
IO checkpoint blockade has become standard of care for many indications.
The patient progressed on osimertinib and will switch to antibody-drug conjugate therapy.
Tagrisso was well-tolerated throughout the radiation therapy course.
Carboplatin-based chemoradiation is followed by maintenance immunotherapy.
